Philip P. Crowley Esq. is the founder and Managing Partner at Crowley Law LLC, a boutique corporate law firm focused on helping emerging tech and life sciences startups launch and reach their full potential. Phil guides clients in forming and structuring new business entities including mergers and acquisitions. As a trusted advisor, he guides entrepreneurs in strategic business initiatives including contract review and negotiation, licensing, IP planning and protection, and founders and key employee arrangements. Phil’s main objectives are to help startup businesses proactively avoid costly mistakes while laying a solid foundation for business growth and success. In addition to providing an analysis of and planning strategy for protection against liabilities, Phil provides ongoing proactive counseling services for clients without in-house counsel.
Prior to launching the firm, Phil served as a Corporate Counsel for Johnson & Johnson. In this role, Phil was a valuable partner for Johnson & Johnson’s diversified businesses and provided strategic legal guidance in the areas of mergers & acquisitions, finance & commercial law, FDA regulations and environmental compliance.
Phil is a Trustee of Stevens Institute of Technology, a member of the Board of Directors of Ben Franklin Technology Partners of Northeastern Pennsylvania, and former Mentor to the Florida Atlantic University TechLaunch program. Phil leverages his connectivity to these organizations to help tech innovators seize opportunities. As a current Mentor to life sciences incubators at Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center & Rockefeller University in NYC, Phil is uniquely qualified to help emerging life sciences companies at every stage in their life cycles.
Structuring your startup equity compensation correctly is often the deciding factor in whether your company survives its first five years. Attracting highly specialized talent, especially...
The equity compensation strategy that launched your biotech company in 2024 requires careful re-evaluation in 2026. Two years ago, your primary goal was distributing equity...
Building a tech or biotech startup requires assembling a world-class team. To attract top-tier engineers, clinical scientists, and seasoned executives, you must offer equity. But...
